All Articles

Antidiabetic medication could prevent dementia

News
October 24, 2022
By
Agnieszka Szmitkowska, Ph.D.

Research associates antidiabetic medication use with a lower risk of dementia in diabetic patients. A study compared three common medications: metformin, sulfonylurea, and thiazolidinedione.

Type 2 diabetes (T2D) is related to a higher risk of all-cause dementia including Alzheimer’s and vascular dementia. The links connecting these two conditions are insulin resistance, hyperglycemia, neuroinflammation, and altered energy homeostasis. Initial research highlights the possibility of using antidiabetic medications for dementia prevention and treatment.

Studies associate antidiabetic medication use with a lower risk of dementia in diabetic patients. The use of metformin and thiazolidinedione was reported to improve cognitive function, while sulfonylurea was associated with increased risks of dementia. However, these results were inconsistent.

Using the Veteran Affairs electronic health records, the research team of Tang et al. compared the effects of three commonly prescribed oral antidiabetic medications: metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD) on dementia onset among veterans with T2D. They followed a cohort of patients with T2D over 16 years. Participants were aged ≥60 years at the initiation of antidiabetic medication treatment and were not carrying dementia diagnosis. Based on prescription records, three test groups were assembled:

  • SU monotherapy group
  • TZD monotherapy group
  • control group treated with MET monotherapy

Participants needed to take the assigned treatment for at least one year. All-cause dementia and the two secondary outcomes – Alzheimer’s and vascular dementia – were observed.

Among the 559,106 eligible veterans studied, the all-cause dementia rate was 8.2 cases per 1000 person-years. TZD monotherapy proved to lead to a 22% lower risk of all-cause dementia onset than MET monotherapy and 11% lower for dual therapy of MET and TZD. Interestingly, the risk was 12% higher for SU monotherapy after at least one year of treatment. Supplementing SU treatment with either MET or TZD may offset its pro-dementia effects.

Thanks to the results of this research, future studies for repurposing oral antidiabetic agents for dementia prevention may consider prioritizing thiazolidinedione use. Patients taking SU could be at a higher risk of dementia than MET or TZD users, and regularly checking cognitive functions is more important to this group.

Source: Tang X, Brinton R, Chen Z, Farland L, Klimentidis Y, Migrino R, Reaven P, Rodgers K, Zhou J. Use of oral diabetes medications and the risk of incident dementia in US veterans aged≥ 60 years with type 2 diabetes. BMJ open diabetes research & care. 2022 Jan 1;10(5).

Type 2 diabetes (T2D) is related to a higher risk of all-cause dementia including Alzheimer’s and vascular dementia. The links connecting these two conditions are insulin resistance, hyperglycemia, neuroinflammation, and altered energy homeostasis. Initial research highlights the possibility of using antidiabetic medications for dementia prevention and treatment.

Studies associate antidiabetic medication use with a lower risk of dementia in diabetic patients. The use of metformin and thiazolidinedione was reported to improve cognitive function, while sulfonylurea was associated with increased risks of dementia. However, these results were inconsistent.

Using the Veteran Affairs electronic health records, the research team of Tang et al. compared the effects of three commonly prescribed oral antidiabetic medications: metformin (MET), sulfonylurea (SU), and thiazolidinedione (TZD) on dementia onset among veterans with T2D. They followed a cohort of patients with T2D over 16 years. Participants were aged ≥60 years at the initiation of antidiabetic medication treatment and were not carrying dementia diagnosis. Based on prescription records, three test groups were assembled:

  • SU monotherapy group
  • TZD monotherapy group
  • control group treated with MET monotherapy

Participants needed to take the assigned treatment for at least one year. All-cause dementia and the two secondary outcomes – Alzheimer’s and vascular dementia – were observed.

Among the 559,106 eligible veterans studied, the all-cause dementia rate was 8.2 cases per 1000 person-years. TZD monotherapy proved to lead to a 22% lower risk of all-cause dementia onset than MET monotherapy and 11% lower for dual therapy of MET and TZD. Interestingly, the risk was 12% higher for SU monotherapy after at least one year of treatment. Supplementing SU treatment with either MET or TZD may offset its pro-dementia effects.

Thanks to the results of this research, future studies for repurposing oral antidiabetic agents for dementia prevention may consider prioritizing thiazolidinedione use. Patients taking SU could be at a higher risk of dementia than MET or TZD users, and regularly checking cognitive functions is more important to this group.

Source: Tang X, Brinton R, Chen Z, Farland L, Klimentidis Y, Migrino R, Reaven P, Rodgers K, Zhou J. Use of oral diabetes medications and the risk of incident dementia in US veterans aged≥ 60 years with type 2 diabetes. BMJ open diabetes research & care. 2022 Jan 1;10(5).

Article reviewed by
Dr. Ana Baroni MD. Ph.D.
SCIENTIFIC & MEDICAL ADVISOR
Quality Garant
Close

Dr. Ana Baroni MD. Ph.D.

Scientific & Medical Advisor
Quality Garant

Ana has over 20 years of consultancy experience in longevity, regenerative and precision medicine. She has a multifaceted understanding of genomics, molecular biology, clinical biochemistry, nutrition, aging markers, hormones and physical training. This background allows her to bridge the gap between longevity basic sciences and evidence-based real interventions, putting them into the clinic, to enhance the healthy aging of people. She is co-founder of Origen.life, and Longevityzone. Board member at Breath of Health, BioOx and American Board of Clinical Nutrition. She is Director of International Medical Education of the American College of Integrative Medicine, Professor in IL3 Master of Longevity at Barcelona University and Professor of Nutrigenomics in Nutrition Grade in UNIR University.

DISCOVER
HealthyLongevity.guide
4.6 / 5
Professional science-based education
250+ Articles, video lectures, webinars
Community of 1000+ verified professionals
Sign Up

Read the latest articles

News
HealthyLongevity.guide

Longevity Conferences 2023

January 19, 2023

Curated list of Longevity Conferences, where you can explore the latest research and developments in the field of aging and longevity.

Ehab Naim, MBA.
News
Body
Diagnostics
Medicine

Vascular endothelial senescence: Exploring current and future diagnostic and therapeutic potential

January 18, 2023

Researchers examined endothelial dysfunction, and identified its causes and effects. They evaluated the use of senotherapeutics in fighting age-related ailments.

Ehab Naim, MBA.
News
Nutrition

A Controlled Trial: Eating Almonds May Help in Reducing Obesity

January 4, 2023

Almond consumption might affect appetite and reduce obesity. Researchers analyzed the blood of obese people after eating almonds to find out more.

Reem Abedi
News
Technology
Lifestyle

Physical activity trackers: Shaping behavior to promote healthy aging among older adults

December 29, 2022

Wearing physical activity tracking devices can promote healthy aging, improve population's quality of life, and reduce the risk of non-communicable diseases.

Ehab Naim, MBA.
News
Body
Longevity

Gut microbiota taxa analysis could offer a better definition of a healthy microbiome

December 26, 2022

One of the drivers behind the age-related decline is the gut microbiome. In their study, Ghosh et al. analyzed over 21,000 microbiome profiles from seven databases across five continents.

Ehab Naim, MBA.
News
Nutrition

Flavonols consumption from fruit and vegetables delays cognitive decline

December 23, 2022

Flavonols are a type of flavonoids that slow down the decline in episodic and semantic memory, perceptual speed, and working memory. A study anaylzed what exactly is their impact on cognitive health.

Agnieszka Szmitkowska, Ph.D.
News
Disease

Saffron Combined with Aerobic Exercise to address Type 2 Diabetes Mellitus

December 21, 2022

Rajabi et al. conducted extensive research on type-2 diabetes patients to investigate the effect of aerobic training and Saffron supplementation for two months.

Reem Abedi
Article
Body
Lifestyle

Which Sport is Best for Longevity?

December 20, 2022

Researchers evaluated which sport is best for longevity. Key components of highly beneficial sports are including a social aspect, engaging both arms and legs, or including whole-body movements.

Jiří Kaloč
News
Aging
Lifestyle
Prevention

Simple lifestyle modifications could reduce the risk of dementia

December 16, 2022

American Heart Association defined ideal values and levels for seven modifiable factors that directly affect cardiovascular health. They include physical activity, smoking, or fasting plasma glucose.

Ehab Naim, MBA.
Video
Lifestyle
Longevity

NATURE EXPOSURE & LONGEVITY (Webinar with Sarah Nielson follow-up + recording)

December 15, 2022

Sarah Nielsen explained the impact of nature exposure on heart rate and blood pressure; how it affects cortisol, inflammation, or anti-cancer proteins; and what you can recommend to your clients.

Reem Abedi
News
No Tag Added

Lower birth weight vs. cardiovascular disease in adulthood

December 15, 2022

A recent article published in the Heart journal demonstrates a connection between lower birth weight, the incidence of myocardial infarction, and adverse left ventricular remodeling.

Agnieszka Szmitkowska, Ph.D.
Article
Lifestyle
Prevention
Aging
Longevity
Nutrition

Key Blue Zones patterns could help with physician burnout

December 6, 2022

There are five areas on Earth where people live significantly longer and disease-free into their late years. What makes them so special? People who live there follow nine simple rules.

Agnieszka Szmitkowska, Ph.D.
News
Medicine
Prevention

Daylight saving time (DST) and mortality patterns in Europe

December 5, 2022

Researchers examined whether daylight saving time affects European mortality patterns. They compared the daily death rates (DDR) for 2 months prior to and after each DST transition.

Reem Abedi
News
Disease

Prostaglandin E2 potentially increases susceptibility to influenza A infection in the elderly

November 30, 2022

A new study tested whether age-related elevation in Prostaglandin E2 is a driver that impairs host defense against influenza.

Ehab Naim, MBA.
Article
Lifestyle
Prevention

Future healthy longevity starts at conception

November 29, 2022

The habits we develop as children significantly impact lifespan and healthspan in adulthood. Dietary choices, exercise, or for example daily screen time can lead to lasting changes in the organism.

Agnieszka Szmitkowska, Ph.D.
Article
No Tag Added

Every move counts: Non-exercise physical activity for cardiovascular health and longevity

December 13, 2022

Increasing movement and reducing sedentary time lead to significant reductions in the occurrence of many diseases. It is important to encourage people to increase their non-exercise physical activity.

Reem Abedi
No items found.